Rubicon Research enters the Indian CNS formulations market with the acquisition of Arinna Lifesciences Ltd

Rubicon Research Limited ("Rubicon" or the "Company") today announced the acquisition of an 85% equity ownership in Arinna Lifesciences Limited ("Arinna") from its current shareholders.

With a portfolio of over 60 brands in chronic therapies, Arinna is one of the few domestic formulations companies principally focused on drugs treating conditions of the central nervous system ("CNS") with more than 4,000 prescribers backed by an established distribution network of distributors, stockists and retail pharmacies in India.

This acquisition furthers Rubicon's strategy of leveraging its IP and chronic products portfolio to unlock growth in key markets, particularly in the CNS therapeutic category which has always been a core focus area for Rubicon. Arinna's sales and distribution network provides Rubicon access to patients and prescribers in India for its differentiated offerings, including a strong pipeline of specialty products and drug-device combinations.

Commenting on the acquisition, Parag Sancheti, Rubicon's Chief Executive Officer said "The past decade has demonstrated the effectiveness of Rubicon's playbook of R&D innovation, execution rigor and impeccable compliance standards which enabled us to scale our US revenues by over 32 x from FY15 to FY25 while delivering best-in-class return ratios. Arinna now provides us a launchpad for deploying this playbook in the Indian domestic formulations market.

Strategic M&A has always been integral to Rubicon's strategy and our confidence stems from having successfully integrated and scaled acquisitions to foray into new segments such as US branded specialty in 2024 and nasal products development in 2020.

I am pleased to welcome Vivek and the Arinna team to the Rubicon family."

The transaction values Arinna at an enterprise value of INR 200 Crores on a cash and debt free basis. After accounting for net cash and other necessary adjustments to the enterprise value of Arinna, the purchase consideration has been determined to be approximately INR 175.92 Croresfor secondary acquisition of 85% equity shareholding at a price of INR 158.53 per share. The final consideration remains subject to adjustments on the closing date, if any. For the 9 months ended 31 December 2025, Arinna's provisional revenue and EBITDA were INR 56.7 Crores and 9.5 Crores respectively.

The transaction is expected to close within 30 days upon satisfaction of agreed conditions precedent. Arinna's founder Vivek Seth will retain a 15% ownership interest and continue as Arinna's Managing Director.

Shares of Rubicon Research Limited was last trading in BSE at Rs. 824.55 as compared to the previous close of Rs. 819.60. The total number of shares traded during the day was 6589 in over 333 trades.

The stock hit an intraday high of Rs. 838.95 and intraday low of 819.95. The net turnover during the day was Rs. 5459176.00.

Source : Equity Bulls

Keywords

RubiconResearch INE506V01022 Pharmaceuticals Acquisition ArinnaLifesciences